1.
Proc West Pharmacol Soc
; 44: 15-7, 2001.
Article
in English
| MEDLINE
| ID: mdl-11793965
Subject(s)
Inflammation/pathology , Interleukin-1/physiology , Pain/pathology , Prostaglandin-Endoperoxide Synthases/physiology , Tumor Necrosis Factor-alpha/physiology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antibodies, Blocking/pharmacology , Celecoxib , Cyclooxygenase Inhibitors/pharmacology , Diclofenac/pharmacology , Female , Formaldehyde , Inflammation/chemically induced , Interleukin-1/antagonists & inhibitors , Male , Pain/chemically induced , Pain Measurement/drug effects , Pyrazoles , Rats , Rats, Wistar , Sulfonamides/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors
2.
Eur J Pharmacol
; 340(2-3): 177-80, 1997 Dec 11.
Article
in English
| MEDLINE
| ID: mdl-9537812
ABSTRACT
The effect of inhibition of nitric oxide synthesis and guanylate cyclase on the peripheral antinociceptive effect of morphine was assessed by using the formalin test in the rat. Saline, N(G)-monomethyl-L-arginine, a nitric oxide synthesis inhibitor (50 microg) and methylene blue, a guanylate cyclase inhibitor (500 microg), did not exhibit any antinociceptive activity. However, morphine (10 microg) produced a significant antinociceptive effect in phases 2a and 2b, which was reduced by pretreatment with either N(G)-monomethyl-L-arginine or methylene blue. These results suggest that the local administration of morphine induces antinociception by the activation of the L-arginine-nitric oxide-cGMP pathway.
